Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention - Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
Impact of anemia in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention - Analysis from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Trial
复制标题
DOI：
10.1016/j.jacc.2004.03.080
复制
发表时间：
2004-08-04
影响因子：
24
通讯作者：
Stone, GW
中科院分区：
文献类型：
--
作者：
Nikolsky, E;Aymong, ED;Stone, GW
我们试图研究贫血对急性心肌梗死（AMI）患者直接经皮冠状动脉介入治疗（PCI）的影响。背景贫血对直接PCI预后的重要性尚不清楚。（CADILLAC）试验中，2,082例在发病12小时内接受直接PCI的任何年龄的AMI患者随机接受球囊血管成形术与支架术，每种阿昔单抗。根据世界卫生组织（WHO）标准（红细胞压积）定义的基线贫血情况对结局进行分层
OBJECTIVES We sought to investigate the impact of anemia in patients with acute myocardial infarction (AMI) undergoing primary percutaneous coronary intervention (PCI).BACKGROUND The prognostic importance of anemia on primary PCI outcomes is unknown.METHODS In the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial, 2,082 patients of any age with AMI within 12 h onset undergoing primary PCI were randomized to balloon angioplasty versus stenting, each abciximab. Outcomes were stratified by the presence of anemia at baseline, as defined by World Health Organization criteria (hematocrit